BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Launches Bold AI-Driven Strategy to Reach $50 Million Valuation and Target NASDAQ Uplisting 

Fifty 1 Labs (OTC: FITY), a Nevada-based innovator in AI-driven drug repurposing and functional medicine, unveiled a strategic “Game Plan” aimed at achieving a $50 million valuation and uplisting to the OTCQB by Q1 2026, with long-term plans to join the NASDAQ Capital Market. Backed by a $350,000 insider investment and leadership salary deferrals, FITY is advancing its wholly owned subsidiary, Fifty1 AI Labs LLC, with a $1 million R&D initiative to discover repurposed treatments by May 2026. The company will launch a digital platform by July 31, 2025, pursue biotech acquisitions in the $5–10 million range, and host a Q3 2025 shareholder event. With a leadership team including Nobel laureate Dr. James Orbinski and NFL veteran Brandon Spikes, FITY aims to disrupt the $320.6 billion functional medicine market and expand into personalized AI-powered healthcare solutions.

To view the full press release, visit https://ibn.fm/pflbn

About Fifty 1 Labs, Inc.

Fifty 1 Labs, Inc. (OTC: FITY), a Nevada corporation based at 751 North Drive, Melbourne, FL 32934, is a holding company driving innovation in health, wellness, and biotechnology. FITY owns 100% of Genetic Networks LLC, a Delaware-based biotech firm founded in 2015 by Dr. Gennaro D’Urso. Genetic Networks, headquartered in Miami, Florida, develops the GeneScape™ platform, a yeast-based, whole-genome analysis tool that accelerates drug discovery for personalized medicine, biodefense, and wellness applications, with proven success serving major pharma clients like Bristol Myers Squibb. FITY also wholly owns 51, LLC, its sports nutrition subsidiary offering a premium line of supplements—including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies—designed to enhance athletic performance, recovery, and overall health. The Quickness, Astound NMN, and Drago Knives have been merged out of the company and are no longer part of Fifty 1 Labs, Inc., sharpening FITY’s focus on biotech and wellness synergies to empower individuals and organizations worldwide.

For more information, visit the company’s website at https://fifty1labs.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN